Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy
出版年份 2020 全文链接
标题
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy
作者
关键词
-
出版物
Cancer Medicine
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-12-22
DOI
10.1002/cam4.3638
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase II trial of aflibercept with FOLFIRI as a 2nd-line treatment for Japanese patients with metastatic colorectal cancer
- (2019) Tadamichi Denda et al. CANCER SCIENCE
- Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
- (2019) Takeshi Suzuki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
- (2019) Yojiro Hashiguchi et al. International Journal of Clinical Oncology
- The role of tumor angiogenesis as a therapeutic target in colorectal cancer
- (2018) Francesca Battaglin et al. Expert Review of Anticancer Therapy
- Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
- (2018) Naoki Fukuda et al. Oncotarget
- Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials
- (2017) Martin D. Berger et al. EUROPEAN JOURNAL OF CANCER
- An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients
- (2015) W Ichikawa et al. BRITISH JOURNAL OF CANCER
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
- (2012) Richard M. Steingart et al. AMERICAN HEART JOURNAL
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer
- (2012) Sachi Morita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
- (2012) Justin N. Bottsford-Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
- (2010) Zhe-Yi Hu et al. EUROPEAN JOURNAL OF CANCER
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
- (2009) Carie S. Facemire et al. HYPERTENSION
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- Angiogenesis as a strategic target for ovarian cancer therapy
- (2008) Whitney A Spannuth et al. Nature clinical practice. Oncology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now